Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome

Cytotherapy

Volumn 10, Issue 1, 2008, Pages 45-53

  Novitzky, N ^a   Thomas, V ^a   du Toit, C ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

CD52; Graft vs. host disease; Plasma cell malignancies; T cell depletion; Total lymphoid irradiation

Indexed keywords

ALEMTUZUMAB; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; BUSULFAN; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN ALBUMIN; MELPHALAN; OFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; PREDNISONE; PYRROLE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VALACICLOVIR; VALGANCICLOVIR; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANDIDA ALBICANS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MALE; MONOTHERAPY; MORTALITY; MULTIPLE MYELOMA; MULTIPLE REGRESSION; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SEPTICEMIA; SIBLING; SURVIVAL TIME; T CELL DEPLETION; VIRUS REACTIVATION; WHOLE BODY RADIATION;

EID: 38349160448     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701732771     Document Type: Article

References (34)

1. Cavo, M., Benni, M. and Ronconi, S. (2002) Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: Final analysis of a randomized clinical study. Haematologica, 87, pp. 934-942.
2. Cornwell, GG, Pajak, TF and Kochwa, S. (1982) Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma: Cancer and Leukemia Group B experience. Cancer, 50, pp. 1669-1675.
3. Oken, MM. (1984) Multiple myeloma. Med Clin North Am, 68, pp. 757-787.
4. Bensinger, WI, Rowley, SD and Demire, T. (1996) High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol, 14, pp. 1447-1456.
5. Barlogie, B., Jagannath, S. and Desikan, KR (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, pp. 55-65.
6. Bjorkstrand, B., Hagman, A. and Ljungman, P. (2001) Autologous stem cell transplantation in multiple myeloma: An update of the EBMT registry. European Journal of Haematology, pp. 199-202.
7. Blade, J., Esteve, J. and Rives, S. (2000) High-dose therapy autotransplantation/intensification vs. continued standard chemotherapy in multiple myeloma in first remission: Results of a non-randomized study from a single institution. Bone Marrow Transplant, 26, pp. 845-849.
8. Attal, M., Harousseau, JL and Stoppa, AM (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. New Engl J Med, 335, pp. 91-97.
9. Lenhoff, S., Hjorth, M. and Holmberg, E. (2000) Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study, Nordic Myeloma Study Group. Blood, 95, pp. 7-11.
10. Corradini, P., Voena, C. and Astolfi, M. (1995) High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood, 85, pp. 1596-1602.
11. Stewart, K., Vescio, R. and Schiller, G. (2001) Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol, 19, pp. 3771-3779.
12. Tricot, G., Vesole, DH and Jagannath, S. (1996) Graft-versus-myeloma effect: Proof of principle. Blood, 87, pp. 1196-1198.
13. Bjorkstrand, BB, Ljungman, P. and Svensson, H. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood, 88, pp. 4711-4718.
14. Lokhorst, HM, Schattenberg, A. and Cornelissen, JJ (1997) Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 90, pp. 4206-4211.
15. Lokhorst, HM, Schattenberg, A. and Cornelissen, JJ (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome. J Clin Oncol, 18, pp. 3031-3037.
16. Bensinger, WI, Demirer, T. and Buckner, CD (1996) Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant, 18, pp. 527-531.
17. Novitzky, N., Thomas, V. and Hale, G. (2004) Campath-1 Abs 'in the bag' for hematological malignancies: The Cape Town experience. Cytotherapy, 6, pp. 172-181.
18. Hale, G., Jacobs, P. and Wood, L. (2000) CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant, 26, pp. 69-76.
19. Novitzky, N., Thomas, V. and Hale, G. (2005) Myeloablative conditioning is well tolerated by older patients receiving T-cell depleted grafts. Bone Marrow Transplant, 36, pp. 675-682.
20. Hale, G., Xia, M-Q and Tighe, HP (1990) The CAMPATH-1 antigen (Cdw 52). Tissue Antig, 35, pp. 118-127.
21. Greipp, PR, Miguel, J San and Durie, BG (2005) International staging system for multiple myeloma. J Clin Oncol, 23, pp. 3412-3420.
22. Hickman, RO, Buckner, CD and Clift, RA (1979) A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet, 148, pp. 871-875.
23. Novitzky, N. and Rouskova, A. (2001) Infectious complications following T-cell depleted hematopoietic stem-cell transplantation. Cytotherapy, 3, pp. 165-173.
24. Bern, MM, Lokich, JJ and Wallach, SR (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med, 112, pp. 423-428.
25. Sutherland, DR, Anderson, L. and Keeney, M. (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother, 5, pp. 213-226.
26. Glucksberg, H., Storb, R. and Fefer, A. (1974) Clinical manifestations of graft vs host disease in human recipients of marrow from HLA matched sibling donors. Transplantation, 18, p. 295.
27. Orlowski, RZ, Stinchcombe, TE and Mitchell, BS (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 20, pp. 4420-4427.
28. Barlogie, B., Desikan, R. and Eddlemon, P. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, pp. 492-494.
29. Richardson, P., Schlossman, R. and Hideshima, T. (2001) A phase I trial of oral CC-5013, an immunomodulatory thalidomide derivative, in patients with relapsed and refractory multiple myeloma. Blood, 98, p. 775a.
30. Bjorkstrand, B., Ljungman, P. and Svensson, H. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood, 88, pp. 4711-4718.
31. Lokhorst, HM, Segeren, CM and Verdonck, LF (2003) For the Dutch-Belgian Hemato-Oncology Cooperative Group. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol, 21, pp. 1728-1733.
32. Peggs, KS, Mackinnon, S. and Williams, CD (2003) Reduced-intensity transplantation with in vivo T cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant, 9, pp. 257-265.
33. Crawley, C., Lalancette, M. and Szydlo, R. (2005) Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood, 105, pp. 4532-4539.
34. Morris, EC, Rebello, P. and Thomson, KJ (2003) Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood, 102, pp. 404-406.